Literature DB >> 27356023

Overview and diagnosis of multiple sclerosis.

Samuel F Hunter1.   

Abstract

Multiple sclerosis (MS), a chronic inflammatory disease of unknown etiology, involves an immunemediated attack of the central nervous system (CNS) that produces demyelination and axonal/neuronal damage, resulting in characteristic multifocal lesions apparent on magnetic resonance imaging and a variety of neurologic manifestations. The disease pathology is characterized by multifocal lesions within the CNS, in both the white matter and gray matter, with perivenular inflammatory cell infiltrates, demyelination, axonal transection, neuronal degeneration, and gliosis. MS pathogenesis is complex, as it involves both T- and B-cell mechanisms and is heterogeneous in presentation. Relatively recently, the historical 4 core clinical categories of MS were revised in an effort to improve characterization of the clinical course, better identify where a given patient is positioned in the disease spectrum, and to guide clinical studies. In young and middle-aged adults, MS is one of the most common contributors to neurologic disability, and it exerts detrimental effects on a patient's productivity and health-related quality of life. Typically, patients with MS have a long life span, although healthcare utilization increases over time. As a consequence, the disease places a substantial burden on patients and their caregivers/families, as well as employers, the healthcare system, and society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27356023

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  24 in total

1.  Sphingosine Toxicity in EAE and MS: Evidence for Ceramide Generation via Serine-Palmitoyltransferase Activation.

Authors:  Lawrence G Miller; Jennifer A Young; Swapan K Ray; Guanghu Wang; Sharad Purohit; Naren L Banik; Somsankar Dasgupta
Journal:  Neurochem Res       Date:  2017-05-05       Impact factor: 3.996

2.  Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.

Authors:  G Balloy; J Pelletier; L Suchet; C Lebrun; M Cohen; P Vermersch; H Zephir; E Duhin; O Gout; R Deschamps; E Le Page; G Edan; P Labauge; C Carra-Dallieres; L Rumbach; E Berger; P Lejeune; P Devos; J-B N'Kendjuo; M Coustans; E Auffray-Calvier; B Daumas-Duport; L Michel; F Lefrere; D A Laplaud; C Brosset; P Derkinderen; J de Seze; S Wiertlewski
Journal:  J Neurol       Date:  2018-07-27       Impact factor: 4.849

Review 3.  Vitamin D and Genetic Susceptibility to Multiple Sclerosis.

Authors:  Concetta Scazzone; Luisa Agnello; Giulia Bivona; Bruna Lo Sasso; Marcello Ciaccio
Journal:  Biochem Genet       Date:  2020-11-07       Impact factor: 1.890

Review 4.  Thrombin generation and activity in multiple sclerosis.

Authors:  Kelley R Jordan; Ivan Parra-Izquierdo; András Gruber; Joseph J Shatzel; Peter Pham; Larry S Sherman; Owen J T McCarty; Norah G Verbout
Journal:  Metab Brain Dis       Date:  2021-01-07       Impact factor: 3.584

5.  Test-retest reliability of static postural control in people with multiple sclerosis.

Authors:  Maria Mercedes Reguera-García; Fernanda de Souza-Teixeira; Jose Antonio de Paz Fernández
Journal:  J Phys Ther Sci       Date:  2017-08-10

6.  Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database.

Authors:  Aaron Boster; Jacqueline Nicholas; Ning Wu; Wei-Shi Yeh; Monica Fay; Michael Edwards; Ming-Yi Huang; Andrew Lee
Journal:  Neurol Ther       Date:  2017-02-16

7.  Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials.

Authors:  Jutta Gärtner; Tanuja Chitnis; Angelo Ghezzi; Daniela Pohl; Wolfgang Brück; Dieter Adrian Häring; Goeril Karlsson; Norman Putzki
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-05-25

Review 8.  Depression and Suicidality in Multiple Sclerosis: Red Flags, Management Strategies, and Ethical Considerations.

Authors:  Rosalind Kalb; Anthony Feinstein; Amanda Rohrig; Lauren Sankary; Alissa Willis
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-28       Impact factor: 5.081

9.  Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis.

Authors:  Kaja Kasarełło; Emilian Snarski; Dorota Sulejczak; Tomasz Ciesielski; Agnieszka Wiśniewska; Robert Wrzesień; Agnieszka Cudnoch-Jędrzejewska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-06-28       Impact factor: 4.291

10.  Health-related outcomes, health care resource utilization, and costs of multiple sclerosis in Japan compared with US and five EU countries.

Authors:  Kaoru Yamabe; Marco D DiBonaventura; Chris L Pashos
Journal:  Clinicoecon Outcomes Res       Date:  2019-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.